Stockscreener 앱 받기
3.21
0.00%
0.00
시간 외 거래:
3.21
전일 마감가:
$3.21
열려 있는:
$3.18
하루 거래량:
2.57M
Relative Volume:
2.77
시가총액:
$608.27M
수익:
$12.99M
순이익/손실:
$-74.39M
주가수익비율:
-6.9783
EPS:
-0.46
순현금흐름:
$-78.92M
1주 성능:
-7.76%
1개월 성능:
-6.69%
6개월 성능:
+8.81%
1년 성능:
+45.25%
1일 변동 폭
$3.16
$3.26
1주일 범위
$3.13
$3.605
52주 변동 폭
$2.21
$4.725
Arbutus Biopharma Corp Stock (ABUS) Company Profile
명칭
Arbutus Biopharma Corp
전화
604-419-3200
주소
701 VETERANS CIRCLE, WARMINSTER, PA
ABUS을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
ABUS
Arbutus Biopharma Corp
|
3.21 | 608.27M | 12.99M | -74.39M | -78.92M | -0.44 |
|
VRTX
Vertex Pharmaceuticals Inc
|
397.27 | 102.31B | 10.63B | -479.80M | -1.35B | -1.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
701.85 | 77.13B | 13.85B | 4.65B | 3.32B | 40.41 |
|
ARGX
Argen X Se Adr
|
623.82 | 37.30B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
245.44 | 31.66B | 2.09B | -332.26M | 16.06M | -2.62 |
|
BNTX
Biontech Se Adr
|
113.08 | 27.11B | 3.30B | -501.07M | 1.03B | -2.1146 |
Arbutus Biopharma Corp Stock (ABUS) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2022-02-02 | 업그레이드 | Jefferies | Hold → Buy |
| 2021-02-25 | 개시 | Jefferies | Hold |
| 2020-12-17 | 개시 | H.C. Wainwright | Buy |
| 2020-07-27 | 재개 | JMP Securities | Mkt Outperform |
| 2020-07-24 | 다운그레이드 | Robert W. Baird | Outperform → Neutral |
| 2020-05-19 | 업그레이드 | Wedbush | Neutral → Outperform |
| 2020-03-06 | 업그레이드 | Chardan Capital Markets | Neutral → Buy |
| 2020-02-20 | 개시 | Robert W. Baird | Outperform |
| 2020-02-05 | 업그레이드 | JMP Securities | Mkt Perform → Mkt Outperform |
| 2019-10-07 | 재확인 | B. Riley FBR | Buy |
| 2019-10-04 | 다운그레이드 | Chardan Capital Markets | Buy → Neutral |
| 2018-10-16 | 업그레이드 | B. Riley FBR | Neutral → Buy |
| 2018-10-15 | 업그레이드 | Wedbush | Underperform → Neutral |
| 2018-10-12 | 재확인 | Chardan Capital Markets | Buy |
| 2018-07-06 | 다운그레이드 | B. Riley FBR, Inc. | Buy → Neutral |
| 2018-03-19 | 재개 | Chardan Capital Markets | Buy |
| 2018-03-19 | 다운그레이드 | Wedbush | Outperform → Neutral |
| 2018-01-05 | 개시 | B. Riley FBR, Inc. | Buy |
| 2017-04-04 | 업그레이드 | Chardan Capital Markets | Neutral → Buy |
| 2017-02-01 | 재확인 | Wedbush | Outperform |
| 2016-12-13 | 다운그레이드 | Chardan Capital Markets | Buy → Neutral |
| 2016-11-30 | 업그레이드 | Chardan Capital Markets | Neutral → Buy |
모두보기
Arbutus Biopharma Corp 주식(ABUS)의 최신 뉴스
UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC Takes Position in Arbutus Biopharma Co. (NASDAQ:ABUS) - Defense World
UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC Invests $754,000 in Arbutus Biopharma Co. (NASDAQ:ABUS) - MarketBeat
Arbutus Biopharma's SWOT analysis: hepatitis B focus drives stock potential - Investing.com
Arbutus Biopharma (NASDAQ:ABUS) Shares Gap DownHere's Why - MarketBeat
Charles Schwab Investment Management Inc. Purchases 831,663 Shares of Arbutus Biopharma Co. (NASDAQ:ABUS) - MarketBeat
Intech Investment Management LLC Takes Position in Arbutus Biopharma Co. (NASDAQ:ABUS) - Defense World
Large Shareholder Urges Warminster-based Arbutus to Seek Partners Instead of Selling More Stock - BUCKSCO.Today
Here’s Why Arbutus (ABUS) Surged in Q3 - Yahoo Finance
Arbutus Biopharma's SWOT analysis: focus on CHB treatment drives stock outlook - Investing.com
Whitefort Capital Sends Letter to Arbutus Biopharma Board of Directors - The Bakersfield Californian
Arbutus Biopharma's HBV Trial Hits 50% Cure Rate; Major Investor Urges Strategic Partnership - StockTitan
Arbutus Biopharma Co. (NASDAQ:ABUS) Short Interest Update - MarketBeat
Arbutus Biopharma (STU:I9DN) 9-Day RSI : 39.19 (As of Dec. 01, 2024) - GuruFocus.com
Principal Financial Group Inc. Reduces Holdings in Arbutus Biopharma Co. (NASDAQ:ABUS) - Defense World
Arbutus to Participate in H.C Wainwright @ Home Virtual Fireside Chat - Yahoo Finance
Arbutus Biopharma (FRA:I9DN) Price-to-Operating-Cash-Flow : (As of Nov. 25, 2024) - GuruFocus.com
Arbutus Biopharma (STU:I9DN) Days Inventory : 0.00 (As of Sep. 2024) - GuruFocus.com
Arbutus Biopharma (STU:I9DN) Long-Term Debt & Capital Lease Obligation : €0.88 Mil (As of Sep. 2024) - GuruFocus.com
Arbutus Biopharma (NASDAQ:ABUS) Earns "Buy" Rating from Chardan Capital - MarketBeat
HC Wainwright Reiterates Buy Rating for Arbutus Biopharma (NASDAQ:ABUS) - MarketBeat
Arbutus Biopharma’s Clinical Trial Shows Promise for Hepatitis B Treatment - MyChesCo
Arbutus Biopharma Announces Positive Data from Clinical Trials at AASLD – The Liver Meeting® 2024 - Defense World
Promising New Data from Hepatitis B Trial by Arbutus and Barinthus - MyChesCo
Arbutus Biopharma Co. (NASDAQ:ABUS) Short Interest Down 16.0% in October - Defense World
ArriVent BioPharma Reports Advancements and Q3 2024 Financial Results - MyChesCo
Arbutus Biopharma to Showcase Innovations at Jefferies London Healthcare Conference - MyChesCo
Arbutus’ Imdusiran Achieves Functional Cure in cHBV Patients when Combined with a Short Course of Interferon - Yahoo Finance
Two Seas Capital LP Adjusts Stake in Arbutus Biopharma Corp - GuruFocus.com
Arbutus to Present at Jefferies London Healthcare Conference - Yahoo Finance
Creative Planning Raises Stock Holdings in Arbutus Biopharma Co. (NASDAQ:ABUS) - Defense World
HC Wainwright Has Negative Forecast for ABUS FY2024 Earnings - MarketBeat
HC Wainwright Expects Weaker Earnings for Arbutus Biopharma - Defense World
HC Wainwright Reaffirms “Buy” Rating for Arbutus Biopharma (NASDAQ:ABUS) - Defense World
Arbutus Biopharma 8-K Filing: Financial Results and Corporate Presentation Update - Defense World
Arbutus Biopharma Corporation (NASDAQ:ABUS) Q3 2024 Earnings Call Transcript - Insider Monkey
Arbutus Biopharma (NASDAQ:ABUS) Stock Price Expected to Rise, Chardan Capital Analyst Says - Defense World
HC Wainwright Reaffirms Buy Rating for Arbutus Biopharma (NASDAQ:ABUS) - MarketBeat
Arbutus Biopharma Corp (ABUS) Q3 2024 Earnings Call Highlights: Promising Clinical Trials and ... By GuruFocus - Investing.com Canada
Arbutus Biopharma Corp (ABUS) Q3 2024 Earnings Call Highlights: - GuruFocus.com
Arbutus Biopharma Corp (ABUS) Q3 2024 Earnings Call Highlights: Promising Clinical Trials and ... - Yahoo Finance
Arbutus Fades on Q4 Results - Baystreet.ca
Arbutus Biopharma earnings missed, revenue fell short of estimates - Investing.com
Arbutus Biopharma (ABUS) Reports Q3 Loss, Lags Revenue Estimates - Yahoo Finance
Arbutus Biopharma Corp Q3 2024 Earnings: EPS Loss of $0.10 Meets Estimates, Revenue Falls Short at $1.3 Million - GuruFocus.com
Arbutus: Q3 Earnings Snapshot - San Francisco Chronicle
Arbutus Reports Third Quarter 2024 Financial Results and Provides Corporate Update - Yahoo Finance
Arbutus Biopharma (ABUS) Set to Announce Earnings on Wednesday - MarketBeat
Arbutus to Report Third Quarter 2024 Financial Results and Provide Corporate Update - Yahoo Finance
SG Americas Securities LLC Acquires New Position in Arbutus Biopharma Co. (NASDAQ:ABUS) - Defense World
Arbutus Biopharma Target of Unusually High Options Trading (NASDAQ:ABUS) - MarketBeat
Arbutus Biopharma Corp (ABUS) Stock: A Year of Declines and Increases - The InvestChronicle
Arbutus Biopharma Corp (ABUS) 재무 분석
매출
순이익
현금흐름
주당 순 이익
Arbutus Biopharma Corp 주식 (ABUS) 내부자 거래
| 내부자 거래 | 관계 | 날짜 | 거래 | 비용 | #주식 | 가치 ($) | #주식 총계 |
|---|---|---|---|---|---|---|---|
| MANCHESTER KEITH S | Director |
Aug 14 '24 |
Sale |
3.69 |
8,846 |
32,637 |
46,069 |
| Sims Karen | Chief Medical Officer |
Feb 02 '24 |
Sale |
2.31 |
4,358 |
10,078 |
125,542 |
| HASTINGS DAVID C | Chief Financial Officer |
Feb 02 '24 |
Sale |
2.31 |
9,593 |
22,184 |
181,907 |
| Sofia Michael J. | Chief Scientific Officer |
Feb 02 '24 |
Sale |
2.31 |
9,982 |
23,083 |
1,485,121 |
| McElhaugh Michael J. | Interim President & CEO |
Feb 02 '24 |
Sale |
2.31 |
10,164 |
23,504 |
1,504,793 |
2.88%
2.65%
자본화:
|
볼륨(24시간):